Nourish the kidneys! semaglutide has shown strong renal protection and safety in the real world. How can we buy it now?

The Lancet: META analysis of 85000 people shows that GLP-1 drugs such as semaglutide reduce the risk of death from kidney disease

This article, entitled "Effects of GLP-1 receptor agonists on renal and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials", was published in The Lancet diabetes and Endocrinology.

Glucagon like peptide-1 (GLP-1) receptor agonists have been shown to have significant benefits for patients with chronic kidney disease (CKD), diabetes and non diabetes. This is based on the largest and most comprehensive analysis of the renal and cardiovascular outcomes of GLP-1 receptor agonists.

The researchers explained that although GLP-1 receptor agonists have shown benefits for type 2 diabetes, obesity and cardiovascular disease, their effects as chronic kidney disease treatment are not so obvious.

The researchers conducted a meta-analysis of 11 large-scale clinical trials involving a total of 85373 people (67769 of whom had type 2 diabetes, 17604 had overweight or obesity and cardiovascular disease, but no diabetes). Researchers evaluated various GLP-1 receptor agonists, including Ozempic or Wegovy (semaglutide), Trucity (dulaglutide), and Victoza (liraglutide).

Compared to placebo, these receptor agonists were found to reduce the risk of kidney failure by 16% and the risk of renal function deterioration by 22%. Overall, the total risk of kidney failure, deterioration of kidney function, and death due to kidney disease decreased by 19%.

The confirmation of previous research results indicates that GLP-1 receptor agonists can reduce the risk of cardiovascular death, non fatal heart attack, and non fatal stroke by 14% compared to placebo. Analysis shows that individuals taking GLP-1 receptor agonists have a 13% reduction in mortality due to any cause.

"This is the first study to show that GLP-1 receptor agonists have obvious benefits for renal failure or end-stage renal disease, indicating that they play a key role in kidney protection and heart protection treatment for patients with type 2 diabetes, overweight or obesity accompanied by cardiovascular disease or CKD and other common diseases," said Professor Sunil Badve, a professor and researcher at the George Global Health Institute and the University of New South Wales in Sydney.

"Our research will have a significant impact on the clinical guidelines for the management of chronic kidney disease and cardiovascular disease in diabetes patients and non diabetes patients," commented Professor Vlado Perkovic, professor and researcher of George Institute, dean of the University of New South Wales in Sydney and senior author of the research.

More work needs to be done now to apply the results of this study to clinical practice and improve access to GLP-1 receptor agonists for those who benefit from it, "Professor Perkovic added.

Cross border purchase of oral semaglutide and tilboptide, add customer service communication, and obtain your own weight loss plan (licensed pharmaceutical wholesaler in Hong Kong)